Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors
Open Access
- 26 November 2024
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 39 (1) , 33-51
Abstract
Chimeric antigen receptor T-cell therapies have markedly improved the survival rates of patients with B-cell malignancies. However, their efficacy in other hematological cancers, such as acute myeloid leukemia, and in solid tumors has been limited. Key obstacles include the downregulation or loss of antigen expression on cancer cells, restricted accessibility to target cells, and the poor persistence of these “living drugs” because of the highly immunosuppressive tumor microenvironment. Additionally, manufacturing these immunotherapies presents significant challenges, and patients frequently experience side effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This review emphasizes the potential of small-molecule inhibitors, many of which are already approved for clinical use, to facilitate chimeric antigen receptor T-cell manufacturing, enhance their anti-tumor efficacy, and mitigate their side effects. Although substantial work remains, the robust pre-clinical data and the growing clinical interest suggest significant promise for using cancer signaling pathway inhibitors to enhance and refine chimeric antigen receptor T-cell therapy for both hematological and solid tumors. Exploring these combination strategies could lead to more effective therapies, offering new hope for patients with resistant forms of cancer.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (338/1 2021-452881907, SFB/ TRR221)
- Bayerisches Zentrum für Krebsforschung
- Stiftung Deutsche Krebshilfe (70114707, 70115200)
- Bundesministrium für Bildung und Forschung (13N15987, 01EN2306A, 03ZU1111BA)
- H2020 Innovative Medicine Initiative (853988, 945393)
- Hilfe im Kampf gegen den Krebs e.V
- Forschung hilft – Stiftung zur Förderung der Krebsforschung an der Universität Würzburg
- Fraunhofer-Institut für Zelltherapie und Immunologie (20963)
- Universitätsklinikum Würzburg
This publication has 166 references indexed in Scilit:
- Regulation of chromatin by histone modificationsCell Research, 2011
- T Cell ActivationAnnual Review of Immunology, 2009
- Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferationBlood, 2008
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood, 2006
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Enhanced T cell responses due to diacylglycerol kinase ζ deficiencyNature Immunology, 2003
- SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinaseProceedings of the National Academy of Sciences, 2001
- The IAP family: endogenous caspase inhibitors with multiple biological activitiesCell Research, 2000
- JNK is required for effector T-cell function but not for T-cell activationNature, 2000
- Expression and Signal Transduction of the FLT3 Tyrosine Kinase ReceptorActa Haematologica, 1996